Tersera Therapeutics

VARUBI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Tersera Therapeutics

Varubi HCPCS:

J8670

HCPCS Code Descriptor:

Rolapitant, oral, 1 mg

Category:

J Code

Varubi NDCs:

70720-0101-02

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Oral

Varubi CPT Codes:

Potential CPT administration codes for Varubi can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Varubi:

VARUBI is an Oncology-Anti-Emetic drug manufactured by Tersera Therapeutics and administered via the Oral route of administration. The J Code: J8670 is aligned to the drug VARUBI.

ACCESS PRICING AND MORE BY REGISTERING

J8670 Added Date:

January 1, 2017

J8670 Effective Date:

January 1, 2017

J8670 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Varubi billing and coding information.
Varubi patient assistance information can be found through TerSera SupportSource at the URL: https://www.varubirx.com/
VARUBI prescribing information can be found at the link below:
Information regarding VARUBI’s side effects can be found at MedlinePlus